Investigating how a protein affects cholesterol levels in the liver
Official title: Hepatic Rap1a in cholesterol homeostasis
Funded at Columbia University Health Sciences · NIH-10889268 · Data updated 2026-11-12
This study is looking at how a protein called Rap1a helps control cholesterol in the liver, which could lead to better ways to manage cholesterol levels and heart health, especially for those who take cholesterol-lowering medications like statins.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $632,897 |
| NIH project number | 5R01HL165129-02 |
| Project ID | NIH-10889268 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with high cholesterol levels or those at risk for atherosclerotic cardiovascular disease.
✕Less likely to help
Patients who have normal cholesterol levels and are not at risk for cardiovascular diseases may not benefit from this research.
What this research studies
This research focuses on understanding the role of the protein Rap1a in regulating cholesterol levels in the liver, which is crucial for managing cardiovascular diseases. The study aims to explore how Rap1a influences the levels of PCSK9, a protein that affects low-density lipoprotein (LDL) cholesterol, often referred to as 'bad' cholesterol. By examining the cellular mechanisms involved, the researchers hope to identify new therapeutic strategies that could enhance the effectiveness of existing cholesterol-lowering treatments, particularly statins. Patients may benefit from insights that could lead to improved management of cholesterol levels and reduced risk of heart disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that more effectively lower cholesterol levels and reduce the risk of cardiovascular diseases.
How similar studies have gone: Previous research has shown promising results in targeting PCSK9 for cholesterol management, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Ozcan, Lale — Columbia University Health Sciences
- Study coordinator: Ozcan, Lale
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.